R&D channel feed – Endpoints News

R&D channel feed

Novartis drums up anticipation for blockbuster-to-be with PhII data on asthma drug, beating Advair in head-to-head

7 years ago

David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal

7 years ago

Adimab team accuses prominent MIT investigator Ram Sasisekharan of ripping off antibodies and presenting them as his own

7 years ago

BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

7 years ago

PhIII setback mars Ocular's glaucoma drug/device, though company remains 'encouraged' by data breakdown

7 years ago

Merck bets $2.2B on a small cancer drug biotech, snatching it out of the IPO lineup

7 years ago

Cancer research groups urge FDA to overhaul standards for early cell therapy trials, cutting time and cost. But will 'pre-competitive' alliances fly?

7 years ago

Some of the best connected players in the San Diego hub organize launch round for another biotech with an eye on trial data

7 years ago

Long-term inclisiran data suggest The Medicines Company/Alnylam drug will flourish in pivotal study, disrupt 'bad' cholesterol market

7 years ago

$1.3B Keytruda windfall will be used to accelerate translational drug R&D in the UK

7 years ago

Dana-Farber’s 4-year legal battle shines a light on the origins of PD-1 research — forcing a reckoning on who pioneered the landmark cancer breakthrough

7 years ago

AbbVie concedes another PhIII cancer drug flop as glioblastoma defeats latest assault

7 years ago

Following its latest setback, Achillion posts some encouraging PoC data for lead drug

7 years ago

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

7 years ago

After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal

7 years ago

Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech

7 years ago

Analysts spotlight the winners — and losers — on ASCO preview night

7 years ago

Ginkgo BioWorks picks up antibiotics effort with Roche where Warp Drive Bio left off

7 years ago

J&J polishes up its new list of late-stage blockbuster candidates — and cancer remains big

7 years ago

ImmunoGen shares tank (again) after the FDA nixes a shot at an OK for its armed antibody in wake of a failed PhIII

7 years ago

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

7 years ago

Vertex wagers $70M on Kymera and its new fascination with protein degradation

7 years ago

A top exec at struggling Biogen jumps ship for a new job

7 years ago

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

7 years ago

First page Previous page 244 245 246247248 249 250 Next page Last page